分子標的医学

論文

A　欧文

A-a

1．Hirota K, Ooka M, Shimizu N, Yamada K, Tsuda M, Ibrahim MA, Yamada S, Sasanuma H, Masutani M, Takeda S: XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.. Genes to Cells : devoted to molecular & cellular mechanisms 27(5): 331-334, 2022. doi: 10.1111/gtc.12929. (IF: 2.3) ＊

2．Nakamura N, Fujihara H, Kawaguchi K, Yamada H, Nakayama R, Yasukawa M, Kishi Y, Hamada Y, Masutani M: Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo.. International Journal of Molecular Sciences 23(5): 2527, 2022. doi: 10.3390/ijms23052527. (IF: 6.208) ＊

3．Imamichi S, Chen L, Ito T, Tong Y, Onodera T, Sasaki Y, Nakamura S, Mauri P, Sanada Y, Igaki H, Murakami Y, Suzuki M, Itami J, Masunaga S, Masutani M: Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy.. Biology 11(3): 420, 2022. doi: 10.3390/biology11030420. (IF: 5.168) ☆＊

4．Tanaka M, Mushiake M, Takahashi J, Sasaki Y, Yamashita S, Ida C, Masutani M, Miwa M: PARP Inhibitor Decreases Akt Phosphorylation and Induces Centrosome Amplification and Chromosomal Aneuploidy in CHO-K1 Cells.. International Journal of Molecular Sciences 23(7): 3484, 2022. doi: 10.3390/ijms23073484. (IF: 6.208) ＊

5．Sasaki Y, Nakatsuka R, Inouchi T, Masutani M, Nozaki T: Inhibition of Poly (ADP-Ribose) Glycohydrolase Accelerates Osteoblast Differentiation in Preosteoblastic MC3T3-E1 Cells.. International Journal of Molecular Sciences 23(9): 3484, 2022. doi: 10.3390/ijms23095041. (IF: 6.208) ＊

6．Tong Y, Kikuhara S, Onodera T, Chen L, Myat AB, Imamichi S, Sasaki Y, Murakami Y, Nozaki T, Fujimori H, Masutani M: Radiosensitization to γ-Ray by Functional Inhibition of APOBEC3G.. International Journal of Molecular Sciences 23(9): 5069, 2022. doi: 10.3390/ijms23095069. (IF: 6.208) ○☆▽◇＊

7．Takagi M, Ogawa C, Iehara T, Aoki-nogami Y, Ishibashi E, Imai M, Kimura T, Nagata M, Yasuhara M, Masutani M, Yoshimura K, Tomizawa D, Ogawa A, Yonemori K, Morishita A, Miyamoto S, Takita J, Kihara T, Nobori K, Hasebe K, Miya F, Ikeda S, Shioda Y, Matsumoto K, Fujimura J, Mizutani S, Morio T, Hosoi H, Koike R: First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.. Cancer 128(15): 2949-2957, 2022. doi: 10.1002/cncr.34270. (IF: 6.921) ＊

8．Araki T, Hamada K, Myat AB, Ogino H, Hayashi K, Maeda M, Tong Y, Murakami Y, Nakao K, Masutani M: Enhanced Cytotoxicity on Cancer Cells by Combinational Treatment of PARP Inhibitor and 5-Azadeoxycytidine Accompanying Distinct Transcriptional Profiles.. Cancers 14(17): 4171, 2022. doi: 10.3390/cancers14174171. (IF: 6) ○◇＊

9．Maki T, Zhou Z, Irie Y, Matsunaga T, Onodera T, Imamichi S, Sasaki Y, Masutani M, Otaki H, Sakuda E, Tanaka Y, Murota H: Singlet-oxygen photosensitizers with a tetrad structure and a single BODIPY chromophore: An evidence for transition state stabilization of intersystem crossing. Dyes and Pigments 210: 110963, 2022. doi: 10.1016/j.dyepig.2022.110963. (IF: 4.5) ＊

A-b

1．Kondo N, Masutani M, Imamichi S, Matsumoto Y, Nakai K: Strategies for Preclinical Studies Evaluating the Biological Effects of an Accelerator-Based Boron Neutron Capture Therapy System.. Cancer Biotherapy & Radiopharmaceuticals 38(3): 173-183, 2022. doi: 10.1089/cbr.2022.0057. (IF: 3.099) ＊

2．Perico D, Silvestre DD, Imamichi S, Sanada Y, Masutani M, Mauri PL: Systems Biology Approach to Investigate Biomarkers, Boron-10 Carriers, and Mechanisms Useful for Improving Boron Neutron Capture Therapy.. Cancer Biotherapy & Radiopharmaceuticals 38(3): 152-159, 2022. doi: 10.1089/cbr.2022.0053. (IF: 3.099) ＊

A-e-1

1．本田徳鷹, Myat AB, Tong Y, 小野寺貴恵, 梅山泰裕, 谷口寛和, 山口博之, 益谷美都子: 肺がんにおけるtalazoparibのPARP阻害剤としての作用機序の検討(Action mechanism of talazoparib as a PARP inhibitor for lung cancer). 日本癌学会総会記事 81回: P3328, 2022.

2．林康平, Tong Y, Myat AB, 佐々木由香, 小野寺貴恵, 平岡伸介, 中尾一彦, 山田康秀, 益谷美都子: Characterization of ERCC1 isoform functions in drug sensitivity and resistance in cancer cells. 日本癌学会学術総会抄録集(Web) 81st: J-2065, P-2367, 2022.

3 . Tong Y, Chen L, Imamichi S, Sanada Y, 佐々木由香, 野崎中成, Ishiai M, 鈴木実, Masunaga S, 益谷美都子: The roles of GM-CSF and inflammatory/immune cascades in the tumor cell response to boron neutron capture therapy. 日本癌学会学術総会抄録集(Web) 81st: P-1364, 2022.

4 . 佐々木由香, 中塚隆介, 井内拓磨, 益谷美都子, 野崎中成: Establishment of olaparib resistant clones from BRCA1 knockout cancer cells for the exploration of resistance genes.. 日本癌学会学術総会抄録集(Web) 81st: P-1349, 2022.

5 . Myat AB, 小野寺貴恵, 佐々木由香, Takamura T, Koizumi F, 益谷美都子: Analysis of MO2455 action mechanism as a potential anti-cancer agent in cancer cells. 日本癌学会学術総会抄録集(Web) 81st: P-3345, 2022.

6 . Mauri PL, Perico D, Rondina A, DePalma A, Fossa P, D'Ursi P , Masutani M, Sauerwein W: Proteomics approach to investigate the role of boron-containing compounds in medicine. ISBB2022 Abstracts : 2022.

7 . Tong Y, Imamichi S, Sanada Y, Mauri PL, Masutani M: Potential applications of extracellular vesicles in SAS cells after BNCT for proteomic analysis. 第18 回日本中性子捕捉療法学会学術大会抄録集 : S3-5, 2022.

8 . Masutani M, Tong Y, Perico D, Silvestre DD, Chen L, Imamichi S, Sanada Y, Nakamura S, Ishiai M, Igaki H, Suzuki M, Mauri PL: Proteomic analysis of extracellular vesicles in oral cancer SAS cells after BNCT . 第18 回日本中性子捕捉療法学会学術大会抄録集 : P4-03, 2022.

9 . Tong Y, Saraswat B, Myat AB, Sasaki Y, Masutani M: Functional inhibition of APOBEC3G causes radiosensitization to g-ray. 第95回日本生化学会抄録集 : 1P-285, 2022.

10 . Saraswat B, Vadi Velu A, Matsuno K, Takamura T, Koizumi F, Masutani M: Cell death processes induced by a potential anti-cancer agent MO2455 in lymphoma cells. 第45回分子生物学会抄録集 : 2022.

11 . Tong Y, Imamichi S, Chen L, Sasaki Y, Masutani M: Extracellular release of HMGB1 as a biomarker for therapeutic response after BNCT irradiation. 第39回分子病理学研究会抄録集 : 2022.

12 . Vadi Velu A, Saraswat B, Tong Y, Myat AB, Matsuno K, Takamura T, Koizumi F, Masutani M: Cell death responses induced by a potential anti-cancer agent MO2455 in lymphoma U937 cells. 日本薬学会第143年会抄録集 : 2022.

B 邦文

B-e-1

1 . 佐々木 由香,中塚 隆介,野﨑 中成,益谷 美都子 : PARP阻害薬olaparibは骨芽細胞の分化を抑制する. 日本薬理学会年会要旨集 95: 3-P-253, 2022.

2 . 鈴木 実, 松本孔貴,益谷美都子 : 中性子ビーム特性ガイドライン策定委員会-生物WGからの活動報告-. 第18 回日本中性子捕捉療法学会学術大会抄録集 : 30 (S-2), 2022.

3 . 石井賢武、中本恵太郎、井原　誠、吉岡　駿、Ying Tong 、佐々木由香、野崎中成、益谷美都子 : ヒトL-type amino acid transporter (LAT-1)の発現制御の解析 (Characterization for gene expression regulation of L-type amino acid transporter (LAT-1) in human cancer
cells). 第45回分子生物学会抄録集 : 3P-814, 2022.

論文研究業績集計表

論文数一覧

	A-a	A-b	A-c	A-d	A-e	合計	SCI	B-a	B-b	B-c	B-d	B-e	合計	総計
2022	9	2	0	0	12	23	11	0	0	0	0	3	3	26

学会発表数一覧

	A-a	A-b ｼﾝﾎﾟｼﾞｳﾑ	A-b 学会	合計	B-a	B-b ｼﾝﾎﾟｼﾞｳﾑ	B-b 学会	合計	総計
2022	3	1	0	4	0	0	15	15	19

論文総数に係る教員生産係数一覧

	欧文論文総数 / 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 / 欧文論文総数	教員生産係数 (SCI 掲載論文)
2022	0.885	11.500	0.478	5.500

Impact Factor値一覧

	Impact Factor	教員当たりのImpact Factor	論文当たりのImpact Factor
2022	55.919	27.960	5.084